Boardroom Alpha
Start trial
10-Q primary document
ZVRA · Quarterly Report (Form 10-Q) · Filed May 6, 2026

Zevra Therapeutics Inc — 10-Q exhibit

zvra-20260331xex104nmcfarl.htm
Zevra Therapeutics Inc on Boardroom Alpha
Document
Exhibit 10.4
FIRST AMENDMENT
TO THE
EMPLOYMENT AGREEMENT
This [FIRST] AMENDMENT (the “Amendment”) to the Employment Agreement between Zevra Therapeutics, Inc. and [NAME] (the “Agreement”) is made and entered into this 29 day of January, 2026 (the “Effective Date”), by and between Zevra Therapeutics, Inc. (the “Company”) and Neil McFarlane (the “Executive”);
W I T N E S S E T H:
WHEREAS, the Company and the Executive entered into the Agreement effective October 10, 2023; and
WHEREAS, the Company and the Executive now desire to amend the Agreement to remove provisions relating to accelerated vesting of outstanding equity granted on or after the Effective Date upon the occurrence of a termination without “Cause” or for “Good Reason” (each as defined in the Agreement);
NOW, THEREFORE, the Company and the Executive, effective as of the date set forth above, do hereby amend the Agreement as follows:
1.
Section 4(E)(1)(d) of the Agreement shall be deleted in its entirety and replaced with the following:
“(d)    The vesting of each outstanding equity award granted to Executive will accelerate so that such awards will be fully vested as of the Date of Termination. If any equity awards vest based on the attainment of performance goals, the performance goals will be deemed to have been met as of the Date of Termination, unless such greater amount of vesting is provided for in the applicable award agreements. Notwithstanding the foregoing, this Subsection (d) shall not apply with respect to any equity awards granted on or after the Effective Date, and such awards shall be subject to vesting, if at all, pursuant to the terms of the applicable award agreement.”





2.
Except as specifically amended hereby, the Agreement shall remain in full force and effect as prior to this Amendment.


IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the day and year first above written.

ZEVRA THERAPEUTICS, INC.

By: /s/ Rahsaan Thompson, Chief Legal Officer    


/s/ Neil F. McFarlane    
Neil F. McFarlane, CEO

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer